Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Jan 23 | 2024Novo Partners for Oral Obesity Asset; Scholar Rock Announces IND Clearance for Obesity; JNJ Q4 ’23 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other, SGLT2i Jan 22 | 2024SELECT up for CHMP Opinion?; January CHMP Agenda; Akero Initiates Ph3 EFX MASH TrialPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Jan 19 | 2024Dexcom to Build EU Manufacturing Plant; FDA Finds Manufacturing Lapses at Lilly PlantPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring Jan 17 | 2024Lilly to Launch Mounjaro in EU; FDA Posts Libre 3 Android App Recall; Novo Initiates Ph1 Cagrisema Study in Weight Loss MechanismsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 16 | 2024Novo Resumes Shipments of Wegovy doses in US; Amgen to Acquire Cytokinetics?; Dexcom G7 Integrated with t:slim X2 OUS; Novo Initiates Additional Ph3 Ziltivekimab Trial in HF; BI Expands Greece Manufacturing FacilityPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, SGLT2i Jan 11 | 2024JPM 2024 Day 4: MDGL, LXRX, MNKD, AKBA, and XERS; Novartis No Longer Pursuing Cytokinetics AcquisitionPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Jan 10 | 2024JPM 2024 Day 3: TRNS, ESPR, IONS, AMRN, EMBC, and VTRSPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 10 | 2024JPM 2024 Day 2: ABT, PODD, NVO, LLY, AZN, BAY, BMF, TDOC; Embecta Files 510(k) for T2DM Patch Pump; Omada Partners with Amazon for Cardiometabolic ProgramsPurchase Blast$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 08 | 2024JPM 2024 Day 1: DXCM, MDT, AMGN, AKERO, ARWR, CYTO, NVS, VRTX, ALN, REGN; Tandem X2 Control-IQ Integrated with Libre 2 Plus; Supersapiens Launches Diabetes Platform; Novo Ph3 Icosema ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Jan 05 | 2024Lilly Initiates Orforglipron vs. Farxiga Ph3 Trial; Fractyl Selects its Rejuva GLP-1 Gene Therapy; Tiziana Files Patent for Foralumab + GLP-1RA; Merck GLP-1RAs Commentary; Rivus Completes HFpEF Ph2a EnrollmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Jan 04 | 2024Roche Restructures Diabetes Business; Novo Partners for Obesity and MASH; BI Partners with Ribo for MASH; Lilly Issues Open Letter on Off-Label Mounjaro/Zepbound Use; Lilly Launches Diabetes/Obesity Digital Health Program; Evaluate Projects Novo and Lilly to Top 2024 Global New SalesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Jan 03 | 2024Senseonics Provides Implantable CGM Updates; Esperion and Daiichi Sankyo Resolve Litigation; Better Therapeutics and Glooko Partner for AspyreRxPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery Jan 02 | 2024Holiday Hangover: FDA Issues Dasiglucagon CRL for CHI; Cytokinetics Ph3 Aficamten Results; NeuroBo Submits Obesity IND; New O5 Algorithm Trial Observed; Tirzepatide in T1DM Trial; Novo Warns Against Counterfeit Ozempic in US; Glucotrack Preclinical Implantable CGM DataPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Dec 21 | 2023Lilly Partners for Obesity Drug Discovery; Embecta GLP-1RA CommentaryPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Dec 18 | 2023Structure Tx Oral GLP-1RA Ph2a Results; Akero Doses First Patients in EFX Ph3 ProgramPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Dec 15 | 2023Novo Buys Alkermes Manufacturing Facility for Oral Assets; Fractyl Announces New Revita Analysis; AZ Initiates Ph2 Oral PCSK9i Study in Dyslipidemia; Nexletol/Nexlizet Label UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Dec 13 | 2023Alnylam 2023 Pipeline Updates; Pfizer Full-Year 2024 Guidance Call; Zepbound Available Through Ro Body Program; Novo Challenges IRA’s Constitutional Legitimacy; Tandem Source Full Launch in USPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i Dec 11 | 2023SURMOUNT-4 Results Published in JAMA; December CHMP Agenda; Fractyl Health Presents GLP-1RA PGTx Findings at WCIRDC 2023Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Dec 08 | 2023Sanofi 2023 Investor Day Pipeline Updates; Akero Initiates Ph3 EFX MASH Program; Biomea Presents Data at WCIRDC 2023; Matt Rainville Joins TandemPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, SGLT2i Dec 06 | 2023Medtronic Terminates EOFlow Acquistion; t:slim X2 Now Available with Dexcom G7 Integration; Indoco Receives Tentative Approval for Generic InvokanaPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
